THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Tuesday, November 02, 2021
Pharma businesses and contract research organizations have partnered to exploit their combined strengths, accelerate innovation and drug development, and address critical issues such as COVID-19.
FREMONT, CA: Contract research organizations (CROs) serve clinical research in the pharmaceutical, biotech, and medical industries. CROs are recruited to conduct clinical trials and support research to bring life-saving medications and vaccines to market.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The CRO industry has evolved over the decades. It began in the mid-20th century with companies that performed basic animal experiments, and regulations prompted contract research firms in the 1970s and 1980s to grow into clinical studies. A few of the over 1,000 CROs presently serve the global market.
Why Are Pharmaceutical Companies Turning to CROs?
It might take years to bring a medicine product to market, from research to final approval. On average, it costs around $2.6 billion to develop a single new pharmaceutical; this figure includes the cost of failures. Only about 12 percent of novel medication candidates evaluated in clinical trials are ultimately approved by the US Food and Drug Administration (FDA), so the risk is substantial. Pharmaceutical companies are increasingly resorting to CRO to:
Reduce Expenses: Outsourcing is, at its core, a risk mitigation approach. Pharmaceutical businesses' profits have declined significantly in recent years. Collaborating with a CRO has a number of advantages, including reducing or eliminating the requirement for research, people, invest in in-house R&D and manufacturing facilities, and manage an unclear success potential. It can boost success rates and hasten medication discovery and development, resulting in increased profitability.
Managing Drugs and Clinical Trials That Are Increasingly Complex: Drug development has become more complex due to advancements in cell and gene therapies, antibody-drug conjugates, cytotoxic compound-containing products, and in vitro and in vivo processing procedures. CROs are assisting the pharmaceutical business in making up for its lack of innovation. Numerous of them are constantly creating and upgrading technologies for sample analysis, assay validation, and lot release testing before manufacture, focusing on the highest performance requirements, accuracy, and efficiency.
Reduce Time to Market: CROs already have the skills and infrastructure in place to improve the efficiency of crucial services. They can alter medication candidates in real time in response to data obtained during clinical trials. Reduced lead times enable pharmaceutical companies to get a higher rate of return on their investments much sooner. Drug conjugates of difficulties are addressed at each stage of development by an organization built around these services.
More in News